Infants in remote and northern Canadian communities should receive an effective but costly treatment that would help protect them from severe respiratory syncytial virus (RSV) infections, according to the Canadian Paediatric Society.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.